Spondyloarthritis & psoriatic arthritis
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Authors' conclusion
Tofacitinib efficacy and safety were similar in patients with PsA who directly switched from ADA to tofacitinib and those who continued tofacitinib
Study context
- Population
- Patients with active psoriatic arthritis (PsA)
- Participants
- 180 patients
- Comparison
- ADA switched directly to tofacitinib 5 mg BID vs continuing tofacitinib 5 mg BID
- ADA→tofacitinib 5 mg BIDn = 91
- Continuing tofacitinib 5 mg BIDn = 89reference
Methodological detailsopen-label long-term extension (LTE), Phase 3 randomised double-blind parent study
- Open-label LTE
- Phase 3 randomised double-blind parent study
Primary result
As reported in the abstract
Efficacy (ACR20/50/70, PASI75, Health Assessment Questionnaire-Disability Index (HAQ-DI) response, DAPSA ≤ 3.2, MDA, FACIT-Fatigue change) · Month 3 or 6 in the LTE
- Efficacy similar between groups in the Phase 3 study, and maintained to month 3 or 6 in the LTE
Safety
Treatment-emergent adverse events (AEs), serious AEs and serious infections · Months 3 and 12
- Generally similar in the Phase 3 and LTE studies, and between groups within each study
Original publication
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis. Arthritis Res Ther. Published 19 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →